Inovio Pharmaceuticals Inc vs Philip Morris International Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M), while Philip Morris International Inc. trades at $185.86 (market cap $290.24B). The key difference: Philip Morris International Inc. is far larger — about 3695× Inovio Pharmaceuticals Inc's market cap, and Philip Morris International Inc. pays a 3.16% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PM | |
|---|---|---|
Market Cap | $78.55M | $290.24B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $200.17 |
52-Week Low | $0.66 | $144.33 |
Enterprise Value | $49.56M | $333.36B |
Dividend Yield | — | 3.16% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Philip Morris International (PM) trades at $186.22, down 1.77% with mixed technical signals. The company reported strong Q1 and Q2 2026 earnings beats but faces margin pressure from rising costs. Revenue grew to $40.65B in 2025 with a robust 25.56% net income margin. Analyst consensus remains bullish with a $211.17 price target, though recent news highlights challenges including a $500M impairment charge and increased illicit cigarette trade in Europe.
PM offers solid fundamentals with high profitability and dividend yield, but near-term headwinds from cost inflation and regulatory risks warrant caution. The stock's valuation at 25.54x P/E is reasonable given earnings growth potential, making it attractive for long-term investors despite current volatility.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →